Understanding Epac1 to treat diabetic eye disease
Epac1 as a novel therapeutic target for diabetic retinopathy
This research explores a new way to stop vision loss in people with diabetes by targeting a protein called Epac1.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11128703 on NIH RePORTER |
What this research studies
Millions of Americans with diabetes face vision loss from diabetic retinopathy, a condition where abnormal blood vessels grow in the eye. Current treatments, like anti-VEGF injections, help but don't fully reverse the damage and require frequent visits. We are looking for new and better ways to treat this devastating disease. This project uses genetic and drug-based methods to understand how the Epac1 protein contributes to the growth of these harmful blood vessels and other eye problems in diabetic retinopathy. Our goal is to find new targets for more effective treatments.
Who could benefit from this research
Good fit: This foundational research is for individuals with diabetic retinopathy who are seeking future, improved treatment options.
Not a fit: Patients who do not have diabetic retinopathy or related diabetic eye diseases would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new and more effective treatments for diabetic retinopathy, potentially reducing the need for frequent injections and better preserving vision.
How similar studies have performed: While current anti-VEGF treatments show modest benefits, this approach explores a novel molecular pathway, Epac1, which is a new and untested target for diabetic retinopathy.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Cheng, Xiaodong — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Cheng, Xiaodong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.